Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Role of the Microbiome in the Formation and Development of Colorectal Cancer.

Zwinsová B, Brychtová V, Hrivňáková M, Zdražilová-Dubská L, Bencsiková B, Šefr R, Nenutil R, Vídeňská P, Budinská E.

Klin Onkol. 2019 Summer;32(4):261-269. doi: 10.14735/amko2019261.

PMID:
31426641
2.

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.

Bencsikova B, Budinska E, Selingerova I, Pilatova K, Fedorova L, Greplova K, Nenutil R, Valik D, Obermannova R, Sheard MA, Zdrazilova-Dubska L.

BMC Cancer. 2019 Jul 15;19(1):687. doi: 10.1186/s12885-019-5909-5.

3.

Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.

Vyskocil J, Tucek S, Kiss I, Fedorova L, Nevrlka J, Zdrazilova-Dubska L.

Int Immunopharmacol. 2019 Sep;74:105728. doi: 10.1016/j.intimp.2019.105728. Epub 2019 Jul 6.

PMID:
31288153
4.

High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.

Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F.

Eur J Cancer. 2019 Jul;116:107-113. doi: 10.1016/j.ejca.2019.05.011. Epub 2019 Jun 10.

PMID:
31195354
5.

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment.

Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L.

Cancer Immunol Immunother. 2018 Dec;67(12):1919-1929. doi: 10.1007/s00262-018-2166-4. Epub 2018 May 10. Review.

PMID:
29748897
6.

Host-dependent variables: The missing link to personalized medicine.

Demlova R, Zdrazilova-Dubska L, Sterba J, Stanta G, Valik D.

Eur J Surg Oncol. 2018 Sep;44(9):1289-1294. doi: 10.1016/j.ejso.2018.04.014. Epub 2018 Apr 26. Review.

PMID:
29735363
7.

[The hypercholesterolemias in pregnancy: their etiology and diagnostic significance considerations].

Hyánek J, Pehal F, Dubská L, Miková J, Gombíková L, Kubů S, Haláčková P, Feyereisl J, Táborský L.

Ceska Gynekol. Winter 2017;82(6):455-461. Czech.

PMID:
29302979
8.

Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.

Chovanec J, Selingerova I, Greplova K, Antonsen SL, Nalezinska M, Høgdall C, Høgdall E, Søgaard-Andersen E, Jochumsen KM, Fabian P, Valik D, Zdrazilova-Dubska L.

Oncotarget. 2017 Nov 21;8(64):108213-108222. doi: 10.18632/oncotarget.22599. eCollection 2017 Dec 8.

9.

[Can we Observe Ethnic Difference in Basic Blood Tests? Single-institution Data from Cancer Prevention Programme in the Czech Republic].

Řiháček M, Valík D, Vyzula R, Zdražilová Dubská L.

Klin Onkol. Spring 2017;30(Supplementum1):170-173. Czech.

PMID:
28471198
10.

[Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].

Pilatova K, Budinská E, Bensciková B, Nenutil R, Šefr R, Fedorová L, Hanáková B, Brychtová V, Zdražilová Dubská L.

Klin Onkol. Spring 2017;30(Supplementum1):166-169. Czech.

PMID:
28471197
11.

[Lactate Dehydrogenase - Old Tumour Marker in the Light of Current Knowledge and Preanalytic Conditions].

Greplová K, Selingerová I, Valík D, Pilatova K, Češková M, Zdražilová Dubská L.

Klin Onkol. Spring 2017;30(Supplementum1):156-158. Czech.

PMID:
28471194
12.

[Molecular Pathology of Colorectal Cancer, Microsatellite Instability - the Detection, the Relationship to the Pathophysiology and Prognosis].

Brychtová V, Šefr R, Hrstka R, Vídeňská P, Bencsiková B, Hanáková B, Zdražilová Dubská L, Nenutil R, Budinská E.

Klin Onkol. Spring 2017;30(Supplementum1):153-155. Czech.

PMID:
28471193
13.

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.

Demlova R, Valík D, Obermannova R, ZdraŽilová-Dubská L.

Physiol Res. 2016 Dec 21;65(Supplementum 4):S455-S462. Review.

14.

[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].

Bílek O, Bohovicová L, Demlová R, Poprach A, Lakomý R, Zdražilová-Dubská L.

Klin Onkol. Fall 2016;29 Suppl 4(Suppl 4):78-87. Review. Czech.

PMID:
27846725
15.

'Candidatus Rickettsia mendelii', a novel basal group rickettsia detected in Ixodes ricinus ticks in the Czech Republic.

Hajduskova E, Literak I, Papousek I, Costa FB, Novakova M, Labruna MB, Zdrazilova-Dubska L.

Ticks Tick Borne Dis. 2016 Apr;7(3):482-6. doi: 10.1016/j.ttbdis.2016.02.004. Epub 2016 Feb 4.

PMID:
26873811
16.

Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study.

Obermannova R, Dusek L, Greplova K, Jarkovsky J, Sterba J, Vyzula R, Demlova R, Zdrazilova-Dubska L, Valik D.

Neoplasma. 2015;62(6):958-65. doi: 10.4149/neo_2015_116.

PMID:
26458311
17.

[Immunological Aspects in Oncology--Circulating γδ T Cells].

Cibulka M, Selingerová I, Fědorová L, Zdražilová Dubská L.

Klin Onkol. 2015;28 Suppl 2:2S60-8. Review. Czech.

PMID:
26374160
18.

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.

Rihacek M, Bienertova-Vasku J, Valik D, Sterba J, Pilatova K, Zdrazilova-Dubska L.

Biomed Res Int. 2015;2015:792187. doi: 10.1155/2015/792187. Epub 2015 Aug 3. Review.

19.

A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.

Karlsen MA, Høgdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok CA, Stiekema A, Mutz-Dehbalaie I, Rosenthal AN, Moore EK, Schodin BA, Sumpaico WW, Sundfeldt K, Kristjansdottir B, Zapardiel I, Høgdall CK.

Gynecol Oncol. 2015 Sep;138(3):640-6. doi: 10.1016/j.ygyno.2015.06.021. Epub 2015 Jun 16.

PMID:
26086566
20.

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.

Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R, Zdrazilova-Dubska L.

BMC Gastroenterol. 2015 Mar 24;15:37. doi: 10.1186/s12876-015-0266-6.

Supplemental Content

Loading ...
Support Center